Romano Brothers & Co’s Amedisys AMED Stock Holding History

Romano Brothers & Co’s Portfolio AMED Stock Details AMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-50	Closed	-$4.18K	–	325
2022 Q4	$4.18K	Buy	+50	New	+$4.51K	﹤0.01%	865

Other funds holding AMED

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Romano Brothers & Co's AMED Position: Q1 2023 in Review

Romano Brothers & Co sold out of Amedisys (AMED) in Q1 2023, closing a stake of 50 shares — an estimated $4.18K sold.

Romano Brothers & Co first reported a position in AMED in Q4 2022 and held it in 1 quarter. The position peaked at $4.18K in Q4 2022. 281 funds tracked by Wall St. Rank hold AMED as of Q1 2023.

Romano Brothers & Co reported no remaining Amedisys position as of Q1 2023 after selling out during the quarter.
Romano Brothers & Co sold 50 Amedisys shares in Q1 2023, an estimated $4.18K.
Romano Brothers & Co first reported a position in Amedisys in Q4 2022 and held it in 1 quarter.
Romano Brothers & Co's Amedisys position peaked at $4.18K in Q4 2022.
281 funds tracked by Wall St. Rank held Amedisys as of Q1 2023.

Based on Romano Brothers & Co's 13F filing for Q1 2023, filed 13 Apr 2023.